Climb Bio (CLYM) Operating Expenses (2020 - 2026)

Climb Bio's Operating Expenses history runs 7 years deep, the most recent figure standing at $15.2 million for Q1 2026.

• Quarterly Operating Expenses fell 33.92% year-over-year to $15.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.1 million (down 41.12% YoY) and the FY2025 annual result came in at $67.9 million, down 17.24% from the prior year.
• Operating Expenses was $15.2 million for Q1 2026 at Climb Bio, down from $19.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $56.4 million in Q2 2024 and bottomed at $3.0 million in Q1 2024.
• A 5-year average of $14.7 million and a median of $11.7 million in 2024 frame the typical range for Operating Expenses.
• Peak annual rise in Operating Expenses reached 739.62% in 2024, while the deepest fall reached 87.18% in 2024.
• Climb Bio's Operating Expenses stood at $9.6 million in 2022, then tumbled by 46.39% to $5.1 million in 2023, then soared by 113.02% to $10.9 million in 2024, then jumped by 76.85% to $19.3 million in 2025, then declined by 21.17% to $15.2 million in 2026.
• Business Quant data shows CLYM's Operating Expenses at $15.2 million in Q1 2026, $19.3 million in Q4 2025, and $14.9 million in Q3 2025.